Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Michael W. Deininger, J. Graeme Hodgson, Neil P. Shah, Jorge E. Cortes, Dong Wook Kim, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Martin C. Müller, Jin Li, Wendy T. Parker, Stephanie Lustgarten, Tim Clackson, Frank G. Haluska, Francois Guilhot, Hagop M. Kantarjian, Simona Soverini, Andreas Hochhaus, Timothy P. Hughes, Victor M. RiveraSusan Branford

Research output: Contribution to journalArticle

Abstract

BCR-ABL1 kinase domain mutations can confer resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In preclinical studies, clinically achievable concentrations of the third-generation BCR-ABL1 TKI ponatinib inhibit T315I and all other single BCR-ABL1mutants except T315M, which generates a single amino acid exchange, but requires 2 sequential nucleotide exchanges. In addition, certain compound mutants (containing ‡2 mutations in cis) confer resistance. Initial analyses based largely on conventional Sanger sequencing (SS) have suggested that the preclinical relationship betweenBCR-ABL1mutation status and ponatinib efficacy is generally recapitulated in patients receiving therapy. Thus far, however, such analyses have been limited by the inabilityofSStodefinitively identify compound mutations or mutations representing less than ∼20%of total alleles (referred to as "low-level mutations"), aswell as limited patient follow-up. Here we used next-generation sequencing (NGS) to define the baseline BCR-ABL1 mutation status of 267 heavily pretreated chronic phase (CP)-CML patients from the PACE trial, and used SS to identify clonally dominant mutants that may have developed on ponatinib therapy (30.1 months median follow-up). Durable cytogenetic and molecular responses were observed irrespective of baseline mutation status and included patients with compound mutations. No single or compoundmutation was identified that consistently conferred primary and/or secondary resistance to ponatinib in CP-CML patients. Ponatinib is effective in CP-CML irrespective of baseline mutation status.

Original languageEnglish (US)
Pages (from-to)703-712
Number of pages10
JournalBlood
Volume127
Issue number6
DOIs
StatePublished - Feb 11 2016
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Mutation
Protein-Tyrosine Kinases
Phosphotransferases
Nucleotides
ponatinib
Amino Acids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Alleles

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Deininger, M. W., Hodgson, J. G., Shah, N. P., Cortes, J. E., Kim, D. W., Nicolini, F. E., ... Branford, S. (2016). Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 127(6), 703-712. https://doi.org/10.1182/blood-2015-08-660977

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. / Deininger, Michael W.; Hodgson, J. Graeme; Shah, Neil P.; Cortes, Jorge E.; Kim, Dong Wook; Nicolini, Franck E.; Talpaz, Moshe; Baccarani, Michele; Müller, Martin C.; Li, Jin; Parker, Wendy T.; Lustgarten, Stephanie; Clackson, Tim; Haluska, Frank G.; Guilhot, Francois; Kantarjian, Hagop M.; Soverini, Simona; Hochhaus, Andreas; Hughes, Timothy P.; Rivera, Victor M.; Branford, Susan.

In: Blood, Vol. 127, No. 6, 11.02.2016, p. 703-712.

Research output: Contribution to journalArticle

Deininger, MW, Hodgson, JG, Shah, NP, Cortes, JE, Kim, DW, Nicolini, FE, Talpaz, M, Baccarani, M, Müller, MC, Li, J, Parker, WT, Lustgarten, S, Clackson, T, Haluska, FG, Guilhot, F, Kantarjian, HM, Soverini, S, Hochhaus, A, Hughes, TP, Rivera, VM & Branford, S 2016, 'Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients', Blood, vol. 127, no. 6, pp. 703-712. https://doi.org/10.1182/blood-2015-08-660977
Deininger, Michael W. ; Hodgson, J. Graeme ; Shah, Neil P. ; Cortes, Jorge E. ; Kim, Dong Wook ; Nicolini, Franck E. ; Talpaz, Moshe ; Baccarani, Michele ; Müller, Martin C. ; Li, Jin ; Parker, Wendy T. ; Lustgarten, Stephanie ; Clackson, Tim ; Haluska, Frank G. ; Guilhot, Francois ; Kantarjian, Hagop M. ; Soverini, Simona ; Hochhaus, Andreas ; Hughes, Timothy P. ; Rivera, Victor M. ; Branford, Susan. / Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. In: Blood. 2016 ; Vol. 127, No. 6. pp. 703-712.
@article{1ac9f31ab82346958d08eb97d2b048fe,
title = "Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients",
abstract = "BCR-ABL1 kinase domain mutations can confer resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In preclinical studies, clinically achievable concentrations of the third-generation BCR-ABL1 TKI ponatinib inhibit T315I and all other single BCR-ABL1mutants except T315M, which generates a single amino acid exchange, but requires 2 sequential nucleotide exchanges. In addition, certain compound mutants (containing ‡2 mutations in cis) confer resistance. Initial analyses based largely on conventional Sanger sequencing (SS) have suggested that the preclinical relationship betweenBCR-ABL1mutation status and ponatinib efficacy is generally recapitulated in patients receiving therapy. Thus far, however, such analyses have been limited by the inabilityofSStodefinitively identify compound mutations or mutations representing less than ∼20{\%}of total alleles (referred to as {"}low-level mutations{"}), aswell as limited patient follow-up. Here we used next-generation sequencing (NGS) to define the baseline BCR-ABL1 mutation status of 267 heavily pretreated chronic phase (CP)-CML patients from the PACE trial, and used SS to identify clonally dominant mutants that may have developed on ponatinib therapy (30.1 months median follow-up). Durable cytogenetic and molecular responses were observed irrespective of baseline mutation status and included patients with compound mutations. No single or compoundmutation was identified that consistently conferred primary and/or secondary resistance to ponatinib in CP-CML patients. Ponatinib is effective in CP-CML irrespective of baseline mutation status.",
author = "Deininger, {Michael W.} and Hodgson, {J. Graeme} and Shah, {Neil P.} and Cortes, {Jorge E.} and Kim, {Dong Wook} and Nicolini, {Franck E.} and Moshe Talpaz and Michele Baccarani and M{\"u}ller, {Martin C.} and Jin Li and Parker, {Wendy T.} and Stephanie Lustgarten and Tim Clackson and Haluska, {Frank G.} and Francois Guilhot and Kantarjian, {Hagop M.} and Simona Soverini and Andreas Hochhaus and Hughes, {Timothy P.} and Rivera, {Victor M.} and Susan Branford",
year = "2016",
month = "2",
day = "11",
doi = "10.1182/blood-2015-08-660977",
language = "English (US)",
volume = "127",
pages = "703--712",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

AU - Deininger, Michael W.

AU - Hodgson, J. Graeme

AU - Shah, Neil P.

AU - Cortes, Jorge E.

AU - Kim, Dong Wook

AU - Nicolini, Franck E.

AU - Talpaz, Moshe

AU - Baccarani, Michele

AU - Müller, Martin C.

AU - Li, Jin

AU - Parker, Wendy T.

AU - Lustgarten, Stephanie

AU - Clackson, Tim

AU - Haluska, Frank G.

AU - Guilhot, Francois

AU - Kantarjian, Hagop M.

AU - Soverini, Simona

AU - Hochhaus, Andreas

AU - Hughes, Timothy P.

AU - Rivera, Victor M.

AU - Branford, Susan

PY - 2016/2/11

Y1 - 2016/2/11

N2 - BCR-ABL1 kinase domain mutations can confer resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In preclinical studies, clinically achievable concentrations of the third-generation BCR-ABL1 TKI ponatinib inhibit T315I and all other single BCR-ABL1mutants except T315M, which generates a single amino acid exchange, but requires 2 sequential nucleotide exchanges. In addition, certain compound mutants (containing ‡2 mutations in cis) confer resistance. Initial analyses based largely on conventional Sanger sequencing (SS) have suggested that the preclinical relationship betweenBCR-ABL1mutation status and ponatinib efficacy is generally recapitulated in patients receiving therapy. Thus far, however, such analyses have been limited by the inabilityofSStodefinitively identify compound mutations or mutations representing less than ∼20%of total alleles (referred to as "low-level mutations"), aswell as limited patient follow-up. Here we used next-generation sequencing (NGS) to define the baseline BCR-ABL1 mutation status of 267 heavily pretreated chronic phase (CP)-CML patients from the PACE trial, and used SS to identify clonally dominant mutants that may have developed on ponatinib therapy (30.1 months median follow-up). Durable cytogenetic and molecular responses were observed irrespective of baseline mutation status and included patients with compound mutations. No single or compoundmutation was identified that consistently conferred primary and/or secondary resistance to ponatinib in CP-CML patients. Ponatinib is effective in CP-CML irrespective of baseline mutation status.

AB - BCR-ABL1 kinase domain mutations can confer resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). In preclinical studies, clinically achievable concentrations of the third-generation BCR-ABL1 TKI ponatinib inhibit T315I and all other single BCR-ABL1mutants except T315M, which generates a single amino acid exchange, but requires 2 sequential nucleotide exchanges. In addition, certain compound mutants (containing ‡2 mutations in cis) confer resistance. Initial analyses based largely on conventional Sanger sequencing (SS) have suggested that the preclinical relationship betweenBCR-ABL1mutation status and ponatinib efficacy is generally recapitulated in patients receiving therapy. Thus far, however, such analyses have been limited by the inabilityofSStodefinitively identify compound mutations or mutations representing less than ∼20%of total alleles (referred to as "low-level mutations"), aswell as limited patient follow-up. Here we used next-generation sequencing (NGS) to define the baseline BCR-ABL1 mutation status of 267 heavily pretreated chronic phase (CP)-CML patients from the PACE trial, and used SS to identify clonally dominant mutants that may have developed on ponatinib therapy (30.1 months median follow-up). Durable cytogenetic and molecular responses were observed irrespective of baseline mutation status and included patients with compound mutations. No single or compoundmutation was identified that consistently conferred primary and/or secondary resistance to ponatinib in CP-CML patients. Ponatinib is effective in CP-CML irrespective of baseline mutation status.

UR - http://www.scopus.com/inward/record.url?scp=84959331313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959331313&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-08-660977

DO - 10.1182/blood-2015-08-660977

M3 - Article

C2 - 26603839

AN - SCOPUS:84959331313

VL - 127

SP - 703

EP - 712

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -